Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

The issue of multiplicity in noninferiority studies.

Ke C, Ding B, Jiang Q, Snapinn SM.

Clin Trials. 2012 Dec;9(6):730-5. doi: 10.1177/1740774512455370. Epub 2012 Aug 9.

PMID:
22879575
2.

Statins for secondary prevention of cardiovascular disease: the right dose.

Spector R, Snapinn SM.

Pharmacology. 2011;87(1-2):63-9. doi: 10.1159/000322999. Epub 2011 Jan 11. Review.

3.

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.

Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.

Blood Press. 2009;18(6):348-61. doi: 10.3109/08037050903460590.

PMID:
20001655
4.
5.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators.

Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. Epub 2006 May 17.

6.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies.

Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D.

J Hypertens. 2007 Apr;25(4):871-6.

PMID:
17351381
7.

Sex-based short- and long-term survival in patients following complicated myocardial infarction.

Bonarjee VV, Rosengren A, Snapinn SM, James MK, Dickstein K; OPTIMAAL study group.

Eur Heart J. 2006 Sep;27(18):2177-83. Epub 2006 Aug 1.

PMID:
16882677
8.

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators.

Circulation. 2006 Mar 28;113(12):1588-96. Epub 2006 Mar 13.

PMID:
16534012
9.

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA.

Diabetes Care. 2006 Mar;29(3):595-600.

PMID:
16505512
10.

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.

Am J Cardiol. 2005 Dec 1;96(11):1530-6. Epub 2005 Oct 17.

PMID:
16310435
11.

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.

Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B; LIFE Study Group.

J Am Coll Cardiol. 2005 Sep 6;46(5):770-5.

13.

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM.

J Am Soc Nephrol. 2005 Jun;16(6):1775-80. Epub 2005 May 4.

14.
15.

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.

Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.

Hypertension. 2005 Apr;45(4):580-5.

PMID:
15790960
16.

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.

Kjeldsen SE, Lyle PA, Kizer JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group.

J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8.

17.

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.

Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB.

Hypertension. 2005 Jan;45(1):46-52. Epub 2004 Dec 6.

PMID:
15583076
18.

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators.

JAMA. 2004 Jul 7;292(1):55-64. Erratum in: JAMA. 2004 Sep 8;292(10):1178. Dosage error in article text.

PMID:
15238591
19.

Informative noncompliance in endpoint trials.

Snapinn SM, Jiang Q, Iglewicz B.

Curr Control Trials Cardiovasc Med. 2004 Jul 3;5(1):5.

20.

Separate modeling approaches for survival analysis with inaccurate covariate measurements.

Chen C, Snapinn SM.

J Biopharm Stat. 2004 May;14(2):375-87.

PMID:
15206534
21.

Alternatives for discounting in the analysis of noninferiority trials.

Snapinn SM.

J Biopharm Stat. 2004 May;14(2):263-73.

PMID:
15206525
22.

Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial.

Servoss SJ, Wan Y, Snapinn SM, DiBattiste PM, Zhao XQ, Theroux P, Jang IK, Januzzi JL Jr; PRISM-PLUS trial.

Am J Cardiol. 2004 Apr 1;93(7):843-7.

PMID:
15050486
23.

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.

Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P.

Ann Intern Med. 2003 Dec 2;139(11):901-6.

PMID:
14644892
24.

Proportion of treatment effect (PTE) explained by a surrogate marker.

Chen C, Wang H, Snapinn SM.

Stat Med. 2003 Nov 30;22(22):3449-59.

PMID:
14601012
25.

An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.

Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS, Snapinn SM.

Clin Ther. 2003 Apr;25(4):1186-99.

PMID:
12809965
26.

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators.

Kidney Int. 2003 Apr;63(4):1499-507.

28.
29.

Noninferiority trials.

Snapinn SM.

Curr Control Trials Cardiovasc Med. 2000;1(1):19-21.

30.

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.

Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Danish.

PMID:
11601117
31.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.

33.

A discriminant analysis extension to mixed models.

Tomasko L, Helms RW, Snapinn SM.

Stat Med. 1999 May 30;18(10):1249-60.

PMID:
10363343
34.

Power considerations when a continuous outcome variable is dichotomized.

Deyi BA, Kosinski AS, Snapinn SM.

J Biopharm Stat. 1998 May;8(2):337-52.

PMID:
9598427
35.

Survival analysis with uncertain endpoints.

Snapinn SM.

Biometrics. 1998 Mar;54(1):209-18.

PMID:
9574966
36.

A note on assessing the superiority of a combination drug with a specific alternative.

Snapinn SM, Sarkar SK.

J Biopharm Stat. 1996 Jul;6(3):241-51.

PMID:
8854229
37.

Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group.

Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Lindvall K, Snapinn SM, Berning J.

Am Heart J. 1996 Jul;132(1 Pt 1):71-7.

PMID:
8701878
39.

Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.

Williams GW, Davis RL, Getson AJ, Gould AL, Hwang IK, Matthews H, Shih WJ, Snapinn SM, Walton-Bowen KL.

Stat Med. 1993 Mar;12(5-6):481-92. Review.

PMID:
8493426
40.
41.

Estimation of error rates in discriminant analysis with selection of variables.

Snapinn SM, Knoke JD.

Biometrics. 1989 Mar;45(1):289-99.

PMID:
2720056
42.

Hemodynamic effects of lisinopril after long-term administration in congestive heart failure.

Stone CK, Uretsky BF, Linnemeier TJ, Shah PK, Amin DK, Snapinn SM, Rush JE, Langendörfer A, Liang CS.

Am J Cardiol. 1989 Mar 1;63(9):567-70.

PMID:
2537566
43.

Evaluating the efficacy of a combination therapy.

Snapinn SM.

Stat Med. 1987 Sep;6(6):657-65.

PMID:
2961039
44.

Tests of significance using regression models for ordered categorical data.

Snapinn SM, Small RD.

Biometrics. 1986 Sep;42(3):583-92.

PMID:
3567291
45.

A method for constructing case-mix indexes, with application to hospital length of stay.

Shachtman RH, Snapinn SM, Quade D, Freund DA, Kronhaus AK.

Health Serv Res. 1986 Feb;20(6 Pt 1):737-62.

Supplemental Content

Loading ...
Support Center